SCHEMBL3974183

SCHEMBL3974183

N#CC(CC1CC2CCC(C1)N2)(c1ccccc1)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 20/20 0.61
CHRM2 P08172 4/20 0.61
CHRM1 P11229 4/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12794687 1.00 CHRM3 (0.61) CHRM3CHRM2CHRM1
SCHEMBL10316374 1.00 CHRM3 (0.61) CHRM3CHRM2CHRM1
SCHEMBL8880121 0.78 CHRM3 (0.56) CHRM3CHRM2CHRM1
Darotropium SCHEMBL29504618 0.76 CHRM3 (0.97) CHRM3CHRM2CHRM1
SCHEMBL140398 0.76 CHRM3 (1.00) CHRM3CHRM2CHRM1
Darotropium SCHEMBL3682091 0.76 CHRM3 (0.97) CHRM3CHRM2CHRM1
Darotropium SCHEMBL3682092 0.76 CHRM3 (0.97) CHRM3CHRM2CHRM1
Darotropium SCHEMBL16781068 0.76 CHRM3 (0.97) CHRM3CHRM2CHRM1
SCHEMBL12794643 0.76 CHRM3 (1.00) CHRM3CHRM2CHRM1
SCHEMBL140397 0.76 CHRM3 (1.00) CHRM3CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1682142-B1 M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LTD (GB) 2012-07-11 EP disclosed
US-7906531-B2 M3 muscarinic acetylcholine receptor antagonists GLAXO GROUP LIMITED (GB) 2011-03-15 US disclosed
US-20090275604-A1 M3 Muscarinic Acetylcholine Receptor Antagonists GLAXO GROUP LIMITED 2009-11-05 US disclosed
US-7563803-B2 M3 muscarinic acetylcholine receptor antagonists GLAXO GROUP LIMITED (GB) 2009-07-21 US disclosed
US-7439255-B2 Muscarinic acetylcholine receptor antagonists GLAXO GROUP LIMITED (GB) 2008-10-21 US disclosed
US-20070270456-A1 M3 Muscarinic Acetylcholine Receptor Antagonists GLAXO GROUP LIMITED 2007-11-22 US disclosed
US-20070129396-A1 Muscarinic acetylcholine receptor antagonists GLAXO GROUP LIMITED 2007-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129396-A1 Muscarinic acetylcholine receptor antagonists CHRM3, CHRNG, CHRM2 CHRM3 1/4885CHRM2 3/4885CHRM1 19/4885
US-20090275604-A1 M3 Muscarinic Acetylcholine Receptor Antagonists CHRM3, CHRM2, CHRM5 CHRM3 1/4885CHRM2 2/4885CHRM1 8/4885
US-20070270456-A1 M3 Muscarinic Acetylcholine Receptor Antagonists CHRM3, CHRM2, CHRM5 CHRM3 1/4885CHRM2 2/4885CHRM1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.